Savara (SVRA) Equity Average (2011 - 2026)
Savara (SVRA) reported Equity Average of $189.6 million for Q1 2026, up 18.75% year-over-year from $159.6 million in Q1 2025, and up 86.8% on a QoQ basis from $101.5 million in Q4 2025.
Savara (SVRA) has 16 years of Equity Average data on file, last reported at $189.6 million in Q1 2026.
- Quarterly Equity Average rose 18.75% year-over-year to $189.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $189.6 million (up 18.75% YoY) and the FY2025 annual result came in at $187.3 million, up 118.83% from the prior year.
- Equity Average improved to $189.6 million in Q1 2026 per SVRA's latest filing, from $101.5 million in the prior quarter.
- Across five years, Equity Average topped out at $189.6 million in Q1 2026 and bottomed at $48.8 million in Q1 2023.
- The 5-year median for Equity Average is $117.1 million (2023), against an average of $114.0 million.
- The widest annual swing landed in 2023, when Equity Average slumped 65.25%; it then jumped 162.6% in 2025.
- Tracing SVRA's Equity Average over 5 years: stood at $58.0 million in 2022, then increased by 26.2% to $73.1 million in 2023, then surged by 153.5% to $185.4 million in 2024, then sank by 45.26% to $101.5 million in 2025, then jumped by 86.8% to $189.6 million in 2026.
- Per Business Quant, the three latest SVRA Equity Average figures stand at $189.6 million (Q1 2026), $101.5 million (Q4 2025), and $60.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | 189.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 189.59 Mn |
| Dec 31, 2025 | 101.49 Mn |
| Sep 30, 2025 | 60.16 Mn |
| Jun 30, 2025 | 134.17 Mn |
| Mar 31, 2025 | 159.65 Mn |
| Dec 31, 2024 | 185.40 Mn |
| Sep 30, 2024 | 150.54 Mn |
| Jun 30, 2024 | 111.80 Mn |
| Mar 31, 2024 | 60.80 Mn |
| Dec 31, 2023 | 73.14 Mn |
| Sep 30, 2023 | 117.13 Mn |
| Jun 30, 2023 | 92.99 Mn |
| Mar 31, 2023 | 48.83 Mn |
| Dec 31, 2022 | 57.95 Mn |
| Sep 30, 2022 | 121.78 Mn |
| Jun 30, 2022 | 131.76 Mn |
| Mar 31, 2022 | 140.49 Mn |
| Dec 31, 2021 | 149.86 Mn |
| Sep 30, 2021 | 160.31 Mn |
| Jun 30, 2021 | 170.25 Mn |
| Mar 31, 2021 | 119.75 Mn |
| Dec 31, 2020 | 70.50 Mn |
| Sep 30, 2020 | 80.21 Mn |
| Jun 30, 2020 | 85.56 Mn |
| Mar 31, 2020 | 94.51 Mn |
| Dec 31, 2019 | 104.25 Mn |
| Sep 30, 2019 | 109.80 Mn |
| Jun 30, 2019 | 107.30 Mn |
| Mar 31, 2019 | 105.01 Mn |
| Dec 31, 2018 | 113.04 Mn |
| Sep 30, 2018 | 100.28 Mn |
| Jun 30, 2018 | 88.21 Mn |
| Mar 31, 2018 | 106.51 Mn |
| Dec 31, 2017 | 96.98 Mn |
| Sep 30, 2017 | 77.21 Mn |
| Jun 30, 2017 | 42.06 Mn |
| Mar 31, 2017 | -15.76 Mn |
| Dec 31, 2016 | -11.34 Mn |
| Sep 30, 2016 | 14.81 Mn |
| Jun 30, 2016 | 18.55 Mn |
| Mar 31, 2016 | -3.32 Mn |
| Dec 31, 2015 | 3.11 Mn |
| Sep 30, 2015 | 38.04 Mn |
| Jun 30, 2015 | 46.32 Mn |
| Mar 31, 2015 | 15.90 Mn |
| Dec 31, 2014 | 13.47 Mn |
| Sep 30, 2014 | 47.73 Mn |
| Jun 30, 2014 | 51.51 Mn |
| Mar 31, 2014 | 50.30 Mn |
| Dec 31, 2013 | 50.44 Mn |
| Sep 30, 2013 | 55.48 Mn |
| Jun 30, 2013 | 47.23 Mn |
| Mar 31, 2013 | 39.17 Mn |
| Dec 31, 2012 | 44.04 Mn |
| Sep 30, 2012 | 47.68 Mn |
| Jun 30, 2012 | 51.02 Mn |
| Mar 31, 2012 | 54.87 Mn |
| Dec 31, 2011 | 49.97 Mn |
| Sep 30, 2011 | 44.78 Mn |